Suven Life Sciences Limited
Momentum (92/100) does the heavy lifting; quality (33/100) is the drag.
ExpensiveStocksWizard rates Suven Life Sciences Limited a Hold, scoring 52/100 on our blended model. The price is about 15% below its 52-week high of ₹359.55 and 142% above the low of ₹126.65. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 1/9. It clears 7 of 12 investability checks, with durability 33, valuation 9 and momentum 92 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹491.36. Low-confidence estimate — limited data.
1-year price
EOD · 2026-07-3152-week range
-14.59% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold52Piotroski F-score 1/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: -78.8%
- Pass: Low debt (D/E < 0.5): 0.03x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: 4%
- No data: Earnings growing
- Fail: Net margin ≥ 10%: 0.0%
- Pass: Current ratio > 1.5: 17.70
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 162.91
- Fail: Piotroski ≥ 7: 1/9
Quarterly results
Annual financials
Shareholding
- Promoter66.6%
- Institutions2.9%
- Public & other30.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 162.91.
Opportunities
- Trades ~100% below our estimated fair value.
Bear case
Weaknesses
- Low return on equity (-78.8%).
- Weak Piotroski score (1/9).
Threats
- Rich valuation versus sector peers.
About Suven Life Sciences Limited
Suven Life Sciences is a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative disorders through drug discovery and new chemical entities targeting central nervous system diseases. The company operates across India, the United States, Europe, and internationally. Its pipeline includes Masupirdine (SUVN-502) for Alzheimer's disease treatment.
Suven Life Sciences Limited — frequently asked questions
Is Suven Life Sciences Limited a buy, hold or sell?
StocksWizard currently rates Suven Life Sciences Limited (SUVEN) a Hold, based on a blended score of 52/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Suven Life Sciences Limited's fair value?
Our blended DCF and relative-valuation model estimates Suven Life Sciences Limited's fair value at about ₹614.2, versus a current price of ₹307.1 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is Suven Life Sciences Limited financially healthy?
Suven Life Sciences Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 1/9.
How has Suven Life Sciences Limited's share price performed?
Suven Life Sciences Limited is up 49% over three months, and last traded at ₹307.1. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.